Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin
View Patent ↗The present invention relates to inhibiting or preventing infection and protecting against patency complications after a blood catheter has been inserted in a patient comprising administering to the device a pharmaceutically effective amount of a composition comprising: (A) at least one taurinamide derivative, (B) at least one compound selected from the group consisting of biologically acceptable acids and biologically acceptable salts thereof; and (C) heparin at a low concentration.
1. A locking solution composition for treating and reducing infection and flow reduction in blood catheters, wherein the composition comprises a solution of:
a. taurolidine;
b. a biologically acceptable acid in sufficient concentration to bring the pH of the composition into a range that enhances the antimicrobial activity of the taurinamide derivative; and
c. low concentration heparin, in a concentration of 50 to 2500 units per mL of the composition, wherein the heparin concentration is sufficient to prevent reactions of the taurinamide derivative with stagnant blood but low enough that expulsion and/or spillage of the solution into a patient's bloodstream carries a low risk of patient hemorrhage.
2. The composition of claim 1 wherein the biologically acceptable acid is chosen from the group consisting of citric acid and lactic acid.
3. The composition of claim 1 wherein low concentration heparin is in the range of 50 to 1750 units per mL.
4. The composition of claim 1 wherein low concentration heparin is in the range of 50 to 500 units per mL.
5. The composition of claim 1 wherein the low concentration heparin is in the range 50 to 150 units per mL.
6. A method of enhancing the antimicrobial activity and resistance to flow reduction produced by a catheter locking solution comprising taurolidine in combination with a biologically acceptable acid in sufficient concentration to maintain the pH in the range of 5.2 to 6.5, and of protecting the catheter against reaction of taurolidine with blood therein, by adding low concentration heparin in the amount of 50 to 2500 units per mL of the catheter locking solution.
7. The method of claim 6 in which the low concentration heparin is in the range of 50 units per mL to 1750 units per mL.
8. The method of claim 6 in which the low concentration heparin is in the range of 50 units per mL to 500 units per mL.
9. The method of claim 6 in which the low concentration heparin is in the range of 50 units per mL to 150 units per mL.
10. A composition for treating and reducing infection and patency loss in hemodialysis catheters comprising a locking solution comprising:
a. at least one taurolidine which has an antimicrobial activity; and
b. low concentration heparin, in a concentration of 50 to 2500 units per mL of the composition, wherein the heparin concentration is sufficient to prevent reactions of taurolidine with stagnant blood but low enough that expulsion and/or spillage of the solution into a patient's bloodstream carries a low risk of patient hemorrhage.
11. The composition of claim 10 wherein low concentration heparin is in the range of 50 to 1750 units per mL.
12. The composition of claim 10 wherein low concentration heparin is in the range of 50 to 500 units per mL.
13. The composition of claim 10 wherein the low concentration heparin is in the range 50 to 150 units per mL.
14. The composition of claim 1 wherein the solution further comprises a biologically acceptable salt of the biologically acceptable acid.
15. The composition of claim 14 wherein the biologically acceptable salt is chosen from the group consisting of citrate and lactate.
16. The composition of claim 14 wherein the biologically acceptable acid is citric acid, the biologically acceptable salt is citrate, and the pH range is 5.2 to 6.5.
17. The method of claim 6 wherein the catheter locking solution further comprises a biologically acceptable salt of the biologically acceptable acid.
18. The method of claim 6 wherein the biologically acceptable salt is chosen from the group consisting of citrate and lactate.